
As an Amazon Associate and affiliate partner, Menrva Books earns from qualifying purchases. Learn more
A comparative study of cardio protective activity of nebivolol, carvedilol and metoprolol was carried out on doxorubicin-induced cardiac toxicity in rats. The degree of protection was assessed both in vivo by short axis echocardiography measuring ejection fraction (EF), fractional shortening (FS), left ventricular systolic diameter (LVSD) and left ventricular diastolic diameter (LVDD) and in vitro by measuring the inotropic and the chronotropic responses to isoproterenol. Also histopathlogical study was done. This study revealed that there is a significant improvement of cardiac functions in rats treated with β-blockers and there is no significant difference between carvedilol and nebivolol whereas nebivolol has the best histopathological score for improvement cardiac toxicity.
This study investigates the comparative cardioprotective effects of three beta-blockers against doxorubicin-induced cardiac toxicity in rats. The research assesses the efficacy of nebivolol, carvedilol, and metoprolol by examining key echocardiographic parameters such as ejection fraction, fractional shortening, and ventricular diameters in vivo. Additionally, in vitro analysis evaluates the drugs' impact on inotropic and chronotropic responses to isoproterenol, complemented by histopathological examination to quantify cardiac damage.
This research presents a detailed comparative analysis of beta-blocker efficacy in mitigating doxorubicin-induced cardiotoxicity in a rat model. The findings indicate a significant improvement in cardiac function across all tested beta-blockers, with no substantial difference noted between carvedilol and nebivolol in overall functional improvement. However, nebivolol demonstrated superior performance in histopathological scoring, suggesting a more pronounced protective effect at the tissue level. The study contributes valuable data to understanding the differential cardioprotective capacities of these common cardiovascular medications.
Page Count:
148
Publication Date:
2015-01-01
Publisher:
Lap Lambert Academic Publishing GmbH KG
ISBN-10:
3659435651
ISBN-13:
9783659435652
No comments yet. Be the first to share your thoughts!